A Novel Human Epithelial Enteroid Model of Necrotizing Enterocolitis.
Journal
Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252
Informations de publication
Date de publication:
10 04 2019
10 04 2019
Historique:
entrez:
30
4
2019
pubmed:
30
4
2019
medline:
20
3
2020
Statut:
epublish
Résumé
Necrotizing enterocolitis (NEC) is a devastating disease of newborn infants. It is characterized by multiple pathophysiologic alterations in the human intestinal epithelium, leading to increased intestinal permeability, impaired restitution, and increased cell death. Although there are numerous animal models of NEC, response to injury and therapeutic interventions may be highly variable between species. Furthermore, it is ethically challenging to study disease pathophysiology or novel therapeutic agents directly in human subjects, especially children. Therefore, it is highly desirable to develop a novel model of NEC using human tissue. Enteroids are 3-dimensional organoids derived from intestinal epithelial cells. They are ideal for the study of complex physiologic interactions, cell signaling, and host-pathogen defense. In this manuscript we describe a protocol that cultures human enteroids after isolating intestinal stem cells from patients undergoing bowel resection. The crypt cells are cultured in media containing growth factors that encourage differentiation into the various cell types native of the human intestinal epithelium. These cells are grown in a synthetic, collagenous mix of proteins that serve as a scaffold, mimicking the extra-cellular basement membrane. As a result, enteroids develop apical-basolateral polarity. Co-administration of lipopolysaccharide (LPS) in media causes an inflammatory response in the enteroids, leading to histologic, genetic, and protein expression alterations similar to those seen in human NEC. An experimental model of NEC using human tissue may provide a more accurate platform for drug and treatment testing prior to human trials, as we strive to identify a cure for this disease.
Identifiants
pubmed: 31033943
doi: 10.3791/59194
pmc: PMC6814448
mid: NIHMS1055477
doi:
Substances chimiques
Lipopolysaccharides
0
Toll-Like Receptor 4
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : K08 DK106450
Pays : United States
Organisme : NIDDK NIH HHS
ID : R03 DK117216
Pays : United States
Références
Nat Rev Gastroenterol Hepatol. 2016 Nov;13(11):633-642
pubmed: 27677718
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Exp Biol Med (Maywood). 2014 Sep;239(9):1124-34
pubmed: 24719375
Gastroenterology. 1989 Mar;96(3):736-49
pubmed: 2914637
J Vis Exp. 2018 Feb 15;(132):
pubmed: 29553558
Gastroenterology. 2012 Sep;143(3):708-718.e5
pubmed: 22796522
Curr Opin Nephrol Hypertens. 2014 Jul;23(4):399-405
pubmed: 24848937
Cell Mol Gastroenterol Hepatol. 2018 Jan 31;5(4):549-568
pubmed: 29930978
Pharm Res. 1990 Sep;7(9):902-10
pubmed: 2235888
J Immunol. 2007 Oct 1;179(7):4808-20
pubmed: 17878380
J Immunol. 2006 Mar 1;176(5):3070-9
pubmed: 16493066
J Biol Chem. 2016 Feb 19;291(8):3759-66
pubmed: 26677228
J Vis Exp. 2015 Mar 06;(97):null
pubmed: 25866936
J Immunol. 2013 Apr 1;190(7):3541-51
pubmed: 23455503
J Pediatr Surg. 2016 Dec;51(12):1907-1913
pubmed: 27720222
Nat Methods. 2011 Dec 04;9(1):81-3
pubmed: 22138822